文献速递临床试验与 GCP基础与转化研究

依普利酮对肾移植患者血管病变演变的影响(EVATRAN):交叉随机对照试验研究方案

EVATRAN (The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients): study protocol for a cross-over randomized controlled trial.
PubMed 文献 · Trials · 2025-11-07

本研究为随机、开放标签、单中心、交叉试验,纳入36例移植至少1年且维持环孢素治疗的稳定肾移植患者,随机分两组交叉接受依普利酮50 mg/日治疗6个月或无治疗6个月,主要结局为脉搏波速度评估的动脉僵硬度变化,以探讨盐皮质激素受体拮抗剂对血管毒性的影响。

要点

  • 依普利酮50 mg/日治疗6个月对肾移植患者动脉僵硬度的作用尚待试验验证。
  • 交叉设计含4周导入期、8周洗脱期,两组先后接受治疗与无治疗。
  • 次要结局包括血压、内膜中层厚度、左心室质量、氧化应激与内皮功能标志物及移植物功能。

核心结论

  • 通过盐皮质激素受体阻断限制钙调神经磷酸酶抑制剂的血管毒性,可能降低肾移植患者的心血管风险。

研究设计与样本

  • 随机、开放标签、单中心、交叉试验,纳入36例移植至少1年且维持环孢素治疗的稳定肾移植患者。
  • 4周导入期后随机分两组:A组先接受依普利酮50 mg/日治疗6个月,随后6个月无治疗;B组先6个月无治疗,随后依普利酮治疗6个月。
  • 治疗期与无治疗期之间设8周洗脱期。

主要发现

  • 主要结局为6个月依普利酮对动脉僵硬度的作用,通过Sphygmocor®法测量脉搏波速度(PWV),于每个治疗期开始和结束时评估。
  • 次要结局包括中心与外周血压谱、内膜中层厚度、左心室质量、氧化应激与内皮功能障碍标志物、移植物功能标志物(如蛋白尿和肌酐水平)的变化。
  • 监测高钾血症和急性肾功能衰竭发作的发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arterial stiffness is a major prognostic factor of cardiovascular (CV) morbi-mortality in kidney transplant (KT) patients. Preclinical studies have demonstrated that the vascular toxicity of calcineurin inhibitors (CNI) is mediated through the activation of the mineralocorticoid receptor (MR) in vascular smooth muscle cells. Additionally, the role of MR in contributing to arterial stiffness is well documented in non-transplanted individuals. This study aims to investigate the impact of MR antagonist treatment on the progression of arterial stiffness in KT patients on cyclosporine. METHODS: This is a randomized, open-label, single-center, cross-over trial involving 36 stable KT patients who have been transplanted for at least 1 year and are maintained on cyclosporine therapy. After a 4-week run-in period, participants will be randomly assigned to one of two groups. Group A will receive eplerenone at a dose of 50 mg daily for 6 months, followed by a 6-month period without treatment. There will be an 8-week washout phase between the treatment and non-treatment periods. Group B will start with 6 months without treatment, followed by the same 8-week washout phase, and then receive eplerenone for 6 months. The primary outcome is to assess the effect of 6 months of eplerenone on arterial stiffness, measured through pulse wave velocity (PWV) using the Sphygmocor® method at the start and end of each treatment period. Secondary outcomes will include changes in (1) central and peripheral blood pressure profiles, (2) intima-media thickness, (3) left ventricular mass, (4) biomarkers of oxidative stress and endothelial dysfunction, and (5) renal graft function markers, such as proteinuria and creatinine levels. Additionally, the incidence of hyperkalemia and episodes of acute renal failure will be monitored. DISCUSSION: CNI are a key component of immunosuppressive therapy in KT patients. By limiting vascular toxicity through MR blockade, CV risk in these patients may be reduced. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04450953. EudraCT number 2019-004243-74.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Simon A, Girerd N, Jaisser F, et al. EVATRAN (The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients): study protocol for a cross-over randomized controlled trial. Trials. 2025. PMID: 41204172. doi:10.1186/s13063-025-09187-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。